Bioinformatics Disease FDA Approval Magazine 
Drug Discovery World
APRIL 14, 2023
He is being recognised for his revolutionary contributions to developing the first gene-edited cell-based therapy for cancer that involves the genetic re-engineering of a patient’s own T cells to combat their disease, and for demonstrating that adoptive T-cell therapy can induce remission and in some cases cure patients with advanced cancer.
The Pharma Data
JANUARY 21, 2021
I can only hope that their STS experience further inspires them to take on and help solve the biggest challenges facing mankind – from climate change to disease and future pandemics.” About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.
Expert insights. Personalized for you.
130 
Let's personalize your content